Evaluation of the Clinical Efficacy of Y-STRUT® Medical Device Implanted for Contralateral Percutaneous Internal Fixation of Proximal Femur, in Patient With a Low Energy Per Trochanteric Fracture on the First Side
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03648775 |
|
Recruitment Status :
Terminated
(Suspension of the study upon the decision of the notified body)
First Posted : August 27, 2018
Last Update Posted : April 29, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
HIP50 is a national, multicentre, prospective, observational study, in patients presenting a first low energy per trochanteric hip fracture on one side and treated with Y-STRUT® device implanted on the contralateral proximal femur as percutaneous internal fixation to prevent contralateral hip fracture in case of osteoporosis.
The primary objective of this study is to evaluate the clinical efficacy of the studied medical device by measuring the frequency of patient with a fracture at the implantation site within 1 year after implantation.
A total of 50 patients from France will be enrolled (until December 2020) and followed up to 24 months.
| Condition or disease | Intervention/treatment |
|---|---|
| Fracture of Hip Osteoporosis | Device: Y-STRUT® (Hyprevention, Pessac, France) |
| Study Type : | Observational |
| Actual Enrollment : | 10 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | National, Multicentre, Prospective, Observational Study, to Evaluate the Clinical Efficacy of Y-STRUT® Medical Device Implanted for Contralateral Percutaneous Internal Fixation of Proximal Femur, in Patient With a Low Energy Per Trochanteric Fracture on the First Side |
| Actual Study Start Date : | December 6, 2017 |
| Actual Primary Completion Date : | March 24, 2020 |
| Actual Study Completion Date : | March 24, 2020 |
- Device: Y-STRUT® (Hyprevention, Pessac, France)
The studied medical device consists of two components implanted in the proximal femur, combined with bone cement.
- Frequency of post-operative fracture [Clinical efficacy of the device] [ Time Frame: At 12 months ]Frequency of Y-STRUT® implanted patients with a fracture at the implantation site
- Frequency of post-operative fracture [Clinical efficacy of the device] [ Time Frame: At 3 and 24 months ]Frequency of Y-STRUT® implanted patients with a fracture at the implantation site
- Recording of concomitants treatments [safety and feasibility of the device] [ Time Frame: At 3, 12 and 24 months ]Recording of all concomitants treatments: analgesic for pain, anti-osteoporotic treatment and other treatments.
- Pain [safety and feasibility of the device] [ Time Frame: At 3, 12 and 24 months ]Self-evaluation of hip pain using VAS (Visual Analogue Scale), going from 0 (no pain) to 10 (maximum).
- Walking conditions [safety and feasibility of the device] [ Time Frame: At 3, 12 and 24 months ]Assessment of resumption of weight-bearing (yes/no, aid)
- Recording of adverse events and device effects [safety and feasibility of the device] [ Time Frame: At 3, 12 and 24 months ]Recording of the medical device vigilance: all serious adverse events, all adverse events linked to the device or the operative technique, and any other important event reported.
- Surgical procedure duration [learning curve of the procedure] [ Time Frame: At the end of the inclusion period (24 months from the first included patient) ]Measuring mean/median intervention duration of each procedure. Then, all the durations of successive procedures will be compared among all the investigators.
- Hospitalisation duration [learning curve of the procedure] [ Time Frame: At the end of the inclusion period (24 months from the first included patient)] ]Measuring mean/median hospitalisation duration. Then, all the durations of successive hospitalisations will be compared among all the investigators.
- Rate of complications [learning curve of the procedure] [ Time Frame: At the end of the inclusion period (24 months from the first included patient) ]Assessing types and frequencies of procedures complications (per-op and post-op). Then, all the rate of complications will be compared among all the investigators.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 60 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patient of 60 years and older, according to CE indication;
- Patient with information form signed to participate in the study;
- Patients presenting a first low energy hip fracture on one side and having a Y-STRUT® device implanted on the contralateral hip between 0 and 120 days after the treatment of the fracture of the first hip;
Exclusion Criteria:
- Patient who refuse to participate to this study;
- Patient implanted with Y-STRUT® for another indication;
- Patient already enrolled in a clinical study, excluding his participation to HIP50.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03648775
| France | |
| Hôpital Privé d'Ambérieu | |
| Ambérieu-en-Bugey, France, 01500 | |
| Hôpital Antoine Béclère | |
| Clamart, France, 92140 | |
| Centre Hospitalier Universitaire Grenoble Alpes | |
| La Tronche, France, 38700 | |
| Centre Hospitalier Régional Orléans | |
| Orléans, France, 45100 | |
| Nouvelle Clinique de Tours Plus St Gatien | |
| Tours, France, 37000 | |
| Responsible Party: | Hyprevention |
| ClinicalTrials.gov Identifier: | NCT03648775 |
| Other Study ID Numbers: |
HIP50 |
| First Posted: | August 27, 2018 Key Record Dates |
| Last Update Posted: | April 29, 2020 |
| Last Verified: | April 2020 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Osteosynthesis Prophylactic consolidation Proximal femur |
|
Osteoporosis Fractures, Bone Hip Fractures Wounds and Injuries Bone Diseases, Metabolic Bone Diseases |
Musculoskeletal Diseases Metabolic Diseases Femoral Fractures Hip Injuries Leg Injuries |

